Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy).

Marcello MocciaIlaria LopertoRoberta LanzilloAntonio CapacchioneAntonio CarotenutoMaria TriassiVincenzo Brescia MorraRaffaele Palladino

Published in: BMC health services research (2020)

Interferon Beta formulations presented with different prescription patterns, persistence, adherence, healthcare resource utilisation and costs, with Rebif® being used in younger patients and with less MS-related hospital admissions.

Keyphrases

healthcare
multiple sclerosis
end stage renal disease
dendritic cells
ejection fraction
newly diagnosed
chronic kidney disease
mass spectrometry
prognostic factors
metabolic syndrome
patient reported
drug induced